Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Pierre Fabre Laboratories untersuchen das Potenzial der künstlichen Intelligenz, um eine neue Generation klinischer Studien im Bereich der Dermokosmetik zu initiieren

      Pierre Fabre Avene-Logo

      News provided by

      Pierre Fabre Laboratories

      Mar 11, 2026, 20:29 ET

      Share this article

      Share this article


      Von 100 bis 600 Patienten: Um Patienten mit Akne zu unterstützen, verstärkt Avène, die führende Marke der Pierre Fabre Laboratories, die Aussagekraft ihrer klinischen Studien durch Datenanreicherung mittels künstlicher Intelligenz.

      TOULOUSE, Frankreich, 11. März 2026 /PRNewswire/ -- Avène, die führende Marke in französischen Apotheken*, hat in Zusammenarbeit mit dem in Toulouse ansässigen HealthTech-Unternehmen BotDesign einen bedeutenden Durchbruch im Bereich der klinischen Studien zur Dermokosmetik bekannt gegeben.

      Im Jahr 2026 wird Avène eine vergleichende klinische Studie durchführen, um die Wirksamkeit seiner neuen Behandlung für zu Akne neigende Haut, Avène Cleanance Comedomed+, in der Erhaltungsphase nach einer oralen Isotretinoin-Behandlung bei Erwachsenen mit schwerer bis sehr schwerer Akne zu bewerten.

      Continue Reading
      Pierre Fabre Laboratories untersuchen das Potenzial der künstlichen Intelligenz, um eine neue Generation klinischer Studien im Bereich der Dermokosmetik zu initiieren
      Pierre Fabre Laboratories untersuchen das Potenzial der künstlichen Intelligenz, um eine neue Generation klinischer Studien im Bereich der Dermokosmetik zu initiieren

      Avène ist bekannt für seine dermatologische Expertise, die auf therapeutischem Know-how basiert, und engagiert sich seit 1990 für die Verbesserung der Behandlung von Hauterkrankungen. Damit ist Avène die erste Marke, die künstliche Intelligenz in klinischen Studien für Dermokosmetika einsetzt.

      Dies ist ein konkretes Beispiel für die „Supportive Care"-Strategie der Pierre Fabre Laboratories.

      Diese Studie ist in zweierlei Hinsicht einzigartig: aufgrund ihres wissenschaftlichen Anspruchs und weil sie vollständig mit der 2025 eingeführten Strategie der „unterstützenden Pflege" der Pierre Fabre Laboratories im Einklang steht.

      „Wir gehören zu einer Gruppe, die seit jeher in den Bereichen Pharmazeutika und Dermokosmetik verwurzelt ist. Dank unserer medizinischen Expertise verfügen wir über einen Vorsprung beim Verständnis der Patienten und ihrer Erkrankungen. Wir sind ideal positioniert, um auf der Grundlage der Erkrankung Behandlungsprotokolle anzubieten, die Dermokosmetika mit Medikamenten kombinieren. Wir arbeiten bereits an Lösungen, um noch einen Schritt weiter zu gehen, indem wir dermokosmetische Innovationen entwickeln, die die Wirkung der Medikamente verlängern und verstärken oder deren Notwendigkeit hinauszögern können. Da es sich um Dermokosmetika handelt, können sie im Gegensatz zu vielen medikamentösen Behandlungen langfristig angewendet werden", erklärt Dr. Gautier Doat, medizinischer Direktor von Eau Thermale Avène.

      Zum Weiterlesen, https://www.pierre-fabre.com/en/news/avene-artificial-intelligence-clinical-studies-dermo-cosmetics

      Weitere Informationen finden Sie unter www.pierre-fabre.com, @Laboratoires Pierre Fabre, @Pierre Fabre Oncology

      Informationen zu Eau Thermale Avène: https://www.eau-thermale-avene.fr/

      Pressekontakt: Caroline Perdrix Thomas 
      [email protected]

      *Quelle: GERS – SOG Early – Pharmacy Channel – Dermo-cosmetics market definition established by Pierre Fabre laboratories – Origin: Sell Out – Kumulierte Daten bis Dezember 2025 in Volumen (Einheiten) und Wert (Umsatz inkl. Steuern). 

      Foto - https://mma.prnewswire.com/media/2930570/Avene_Cleanance.jpg
      Logo - https://mma.prnewswire.com/media/2930569/PIERRE_FABRE_Avene_Logo.jpg

      Modal title

      Also from this source

      Laboratoires Pierre Fabre: Designación acelerada de la FDA para elticertinib en el NSCLC

      Laboratoires Pierre Fabre: Designación acelerada de la FDA para elticertinib en el NSCLC

      Laboratoires Pierre Fabre anuncia que la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA) ha concedido la designación de «vía...

      Les Laboratoires Pierre Fabre annoncent une procédure accélérée pour l'elticertinib par la FDA pour le traitement du cancer du poumon non à petites cellule

      Les Laboratoires Pierre Fabre annoncent une procédure accélérée pour l'elticertinib par la FDA pour le traitement du cancer du poumon non à petites cellule

      Les Laboratoires Pierre Fabre annoncent que la Food and Drug Administration américaine (FDA) a accordé le statut « Fast Track » à l'elticertinib[i]...

      More Releases From This Source

      Explore

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Pharmaceuticals

      Pharmaceuticals

      Health Care & Hospitals

      Health Care & Hospitals

      STEM (Science, Tech, Engineering, Math)

      STEM (Science, Tech, Engineering, Math)

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.